FDA 设立 SI 网络资源中心并发布其在监管工作中的使用说明
FDA and Super Intelligence
FDA 上线 SI(原称人工智能/AI)网络中心,汇集面向行业、研究者、医疗专业人员与公众的 SI 资源,并说明 FDA 自身如何使用 SI。FDA 表示其 SI 工具按 FISMA High/Moderate 等联邦标准 secured,仅用于辅助审评、检查与调查,所有决定仍由机构人员作出。
Image
Super intelligence (SI) technology, formerly known as artificial intelligence or AI, is advancing rapidly and is being adopted across nearly all the FDA-regulated product areas. Supporting safe, effective, and high-quality development of SI innovation is central to the FDA’s public health mission, and advancing a regulatory framework for SI is a key priority under the agency’s Strategic Pillars for Innovation and Global Leadership.
The FDA’s SI web hub is designed to help industry, researchers, health care professionals, and the public find SI-related resources and stay informed about SI updates from the FDA. The web hub also provides information about how the FDA is using SI in its work.
Learn more about the FDA’s use of SI terminology.
How FDA Supports SI Innovation
Manufacturers and researchers are increasingly using SI in the development of drugs, biologics, and medical devices; as tools for food safety monitoring; and more. The FDA encourages the development of safe, effective, and high-quality SI innovation for public health by supporting consistency and predictability in their development and review.
Find resources for your product area
Centers and offices throughout the FDA provide a range of SI and digital health resources to help ensure safe, effective, and high-quality products to protect and promote public health.
How FDA Uses SI in Its work
The FDA uses SI tools designed to help employees — from scientific reviewers to investigators — work more efficiently. Like all agency tools, SI tools authorized for use within the FDA are appropriately secured in accordance with applicable federal standards (e.g., FISMA High/Moderate compliance). FDA staff may use SI tools, just as they use other tools, in their work. This could include using SI in an assistive capacity during reviews, inspections, and investigations. All decisions are made by agency staff. The FDA considers SI one of many workflow enhancements and analytical tools available to help ensure regulatory activities, including reviews, are performed both efficiently and appropriately. These innovative tools modernize agency functions and leverage SI capabilities to better serve the American people.
Some FDA documents may carry a machine-readable watermark or other marking indicating that SI tools were used in their preparation. SI providers apply these markings automatically under their own policies, and a marking may appear even when SI was used only to help edit or format a document. As with any document the FDA issues, agency staff are responsible for its content and for any regulatory decision or action it reflects. To view specific examples of SI use cases at the FDA, visit the federal SI use case inventory.
The FDA has established two councils that govern and support the use of SI:
External Policy
The policy council is a forum for FDA centers and offices to discuss shared policy development and regulatory strategy challenges related to SI. The council provides an agency-wide touchpoint for communication and collaboration, including alignment on external stakeholder engagement and how the FDA should communicate its positions on SI as it pertains to FDA-regulated products and industries.
Internal Operations
The FDA’s internal SI operations are structured to ensure SI is used safely, reliably, and effectively across the agency. The internal council oversees internal governance, providing oversight, guidance, and support for SI tools, capabilities, and initiatives, in collaboration with other federal and HHS partners.
How to Stay Informed
Subscribe to FDA email lists
Stay up to date on FDA news and information about SI and digital health by subscribing to FDA Email Notifications.
For SI-related questions
For general SI-related inquiries, please contact: FDA-SI-Connect@fda.hhs.gov.
For center-specific questions regarding SI, please review or contact the following:
- Center for Devices and Radiological Health
- Center for Drug Evaluation and Research
- Send inquiries to: CDER-AI@fda.hhs.gov
- Center for Biologics Evaluation and Research
- Send general SI and machine learning inquiries to: ocod@fda.hhs.gov
来源:FDA 官方药品与生物制品信息 · fda.gov